ENABLING PANDEMIC SPEED TO CLINIC FOR SARS-COV2 NEUTRALIZING ANTIBODIES

Peter Onyskiw, Bristol Myers Squibb
peter.onyskiw@bms.com
Ping Xu, Bristol Myers Squibb
May Ou, Bristol Myers Squibb
Monica George, Bristol Myers Squibb
Chaojie Wang, Bristol Myers Squibb
Giovanni Rizzi, , Bristol Myers Squibb
Glenn MacIsaac, Bristol Myers Squibb
Erik Langsdorf, Bristol Myers Squibb
Sen Xu, Bristol Myers Squibb
Kitty Agarwal, Bristol Myers Squibb
Gabi Tremml, Bristol Myers Squibb
Duncan Mcvey, Bristol Myers Squibb
Girish Pendse, Bristol Myers Squibb
Anurag Khetan, Bristol Myers Squibb
Henrik Andersen, Bristol Myers Squibb

Key Words: SARS-CoV2, cell line development, upstream development, pandemic speed

SARS-CoV2 neutralizing monoclonal antibodies have been shown as an effective way to reduce the viral load of patients, minimizing risk of severe illness and hospitalization. BMS has undertaken a considerable effort for rapid commercialization of two such neutralizing antibodies, SARS-CoV2 C135 (Logavimab) and C144 (Crexavimab). Here we present an overview of the cell line and upstream process development efforts conducted at ‘pandemic speed’. These efforts along with several others were critical for enabling the IND submission within 6 months from DNA transfections, followed by a successful clinical supply campaign. Additionally, described are subsequent process developments efforts to further improve the robustness and productivity of the process.